NAS:BGLC (Malaysia)
Â
Ordinary Shares
$
1.68
+0.075 (+4.67%)
10:08 PM EST
Business Description
BioNexus Gene Lab Corp
NAICS : 325998
SIC : 2819
ISIN : US0906283066
Share Class Description:
BGLC: Ordinary SharesTotal Employee Number:
1Description
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 18.36 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.5 | |||||
Beneish M-Score | -4.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.2 | |||||
3-Year EBITDA Growth Rate | -126.9 | |||||
3-Year EPS without NRI Growth Rate | -52.6 | |||||
3-Year Book Growth Rate | -8.2 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.85 | |||||
9-Day RSI | 32.3 | |||||
14-Day RSI | 35.64 | |||||
3-1 Month Momentum % | 14.68 | |||||
6-1 Month Momentum % | -32.25 | |||||
12-1 Month Momentum % | -33.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.53 | |||||
Quick Ratio | 5.69 | |||||
Cash Ratio | 4.98 | |||||
Days Inventory | 75.81 | |||||
Days Sales Outstanding | 74.25 | |||||
Days Payable | 43.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -18.6 | |||||
Shareholder Yield % | 0.64 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 13.95 | |||||
Operating Margin % | -58.61 | |||||
Net Margin % | -54.7 | |||||
EBITDA Margin % | -51.14 | |||||
FCF Margin % | -22.39 | |||||
OCF Margin % | -21.88 | |||||
ROE % | -37.42 | |||||
ROA % | -32.41 | |||||
ROIC % | -69.8 | |||||
3-Year ROIIC % | -2783.5 | |||||
ROC (Joel Greenblatt) % | -100.19 | |||||
ROCE % | -36.54 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.57 | |||||
PB Ratio | 0.5 | |||||
Price-to-Tangible-Book | 0.5 | |||||
EV-to-EBIT | -0.11 | |||||
EV-to-EBITDA | -0.12 | |||||
EV-to-Revenue | 0.06 | |||||
EV-to-FCF | -0.26 | |||||
Price-to-GF-Value | 0.77 | |||||
| Price-to-Net-Current-Asset-Value | 0.95 | |||||
| Price-to-Net-Cash | 1.34 | |||||
Earnings Yield (Greenblatt) % | -909.09 | |||||
FCF Yield % | -29.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BGLC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioNexus Gene Lab Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.311 | ||
| EPS (TTM) ($) | -1.485 | ||
| Beta | 4.0832 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 142.39 | ||
| 14-Day RSI | 35.64 | ||
| 14-Day ATR ($) | 0.195053 | ||
| 20-Day SMA ($) | 2.06626 | ||
| 12-1 Month Momentum % | -33.33 | ||
| 52-Week Range ($) | 1.07 - 8.98 | ||
| Shares Outstanding (Mil) | 2.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioNexus Gene Lab Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioNexus Gene Lab Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2025 | 2026-12-24 09:00 | In 162 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-18 | In 33 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.98 (+1.54%) | ||
| Annual report for 2025 | 2026-04-14 | 2.26 (+4.14%) | ||
| General meeting for 2024 | 2025-12-24 09:00 | 4.10 (+1.61%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 4.52 (+0.22%) | ||
| Second quarter earnings results for 2025 | 2025-08-18 | 5.34 (+0.19%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 2.97 (-1.98%) | ||
| Annual report for 2024 | 2025-04-15 | 2.32 (+1.31%) |
Show
Entries
BioNexus Gene Lab Corp Frequently Asked Questions
What is BioNexus Gene Lab Corp(BGLC)'s stock price today?
The current price of BGLC is $1.68. The 52 week high of BGLC is $8.98 and 52 week low is $1.07.
When is next earnings date of BioNexus Gene Lab Corp(BGLC)?
The next earnings date of BioNexus Gene Lab Corp(BGLC) is 2026-08-18 Est..
Does BioNexus Gene Lab Corp(BGLC) pay dividends? If so, how much?
BioNexus Gene Lab Corp(BGLC) does not pay dividend.
Guru Commentaries on NAS:BGLC
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in BioNexus Gene Lab, Gladstone Investment Corp, Canopy Growth Corp, Recursion Pharmaceuticals, or Monolithic Power Systems? | 2024-02-14 |
Articles on BioNexus Gene Lab Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers